Neonatal sepsis is the cause of substantial morbidity and mortality. Precise estimates of
neonatal sepsis burden vary by setting. Differing estimates of disease burden have been …

Human immunoglobulin preparations for intravenous or subcutaneous administration are
the cornerstone of treatment in patients with primary immunodeficiency diseases affecting …

Sepsis in early infancy results in one million annual deaths worldwide, most of them in
developing countries. No efficient means of prevention is currently available. Here we report …

Neonatal and adult neutrophils are distinctly different from one another due to well-defined
and documented deficiencies in neonatal cells, including impaired functions, reduced …

Despite advances in critical care medicine, neonatal sepsis remains a major cause of
morbidity and mortality worldwide, with the greatest risk affecting very low birth weight …

Objective Identify the progression of specific signs of multiorgan dysfunction among infants
with fatal sepsis. Study Design Cohort study of 679 infants who died within 3 days of the start …

Although late-onset sepsis (LOS) is a major cause of neonatal morbidity and mortality,
biomarkers evaluated in LOS lack high diagnostic accuracy. In this prospective, case …

Intravenous and subcutaneous immunoglobulin preparations, consisting of IgG class
antibodies, are increasingly used to treat a broad range of pathological conditions, including …

Sepsis is the most frequent cause of death in noncoronary intensive care units. In the past
10 years, progress has been made in the early identification of septic patients and their …

A successful immune response is critically necessary to eradicate infectious challenges and
prevent dissemination of the infection in the host. However, if inflammation is not limited and …